References
- Hanna M, Zylicz Z. Cancer pain. New York,NY: Springer; 2013. p. vii & 17.
- Pasetto LM, D’Andrea MR, Rossi E, et al. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006;59:159–168.
- Hoskin PJ. Radiotherapy. Clinical pain management: cancer pain. London: Hodder Arnold; 2008. p. 251–255.
- Portenoy RK. Treatment of cancer pain. Lancet. 2011;377:2236–2247.
- Ghersi D, Willson ML, Chan MM, et al. Taxane-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2015;10(6);Cd003366.
- Dougherty PM, Cata JP, Cordella JV, et al. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004;109:132–142.
- Tanabe Y, Hashimoto K, Shimizu C, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013;18:132–138.
- Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155:2461–2470.
- Kim JH, Dougherty PM, Abdi S. Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy. Gynecol Oncol. 2015;136:453–459.
- Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–1945.
- Banko JL, Poulin F, Hou L, et al. The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. J Neurosci. 2005;25:9581–9590.
- Costa-Mattioli M, Sossin WS, Klann E, et al. Translational control of long-lasting synaptic plasticity and memory. Neuron. 2009;61:10–26.
- Bao Y, Gao Y, Hou W, et al. Engagement of signaling pathways of protease-activated receptor 2 and mu-opioid receptor in bone cancer pain and morphine tolerance. Int J Cancer. 2015;137:1475–1483.
- Geranton SM, Jimenez-Diaz L, Torsney C, et al. A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. J Neurosci. 2009;29:15017–15027.
- Price TJ, Rashid MH, Millecamps M, et al. Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: role of mGluR1/5 and mTOR. J Neurosci. 2007;27:13958–13967.
- Xu Q, Fitzsimmons B, Steinauer J, et al. Spinal phosphinositide 3-kinase-Akt-mammalian target of rapamycin signaling cascades in inflammation-induced hyperalgesia. J Neurosci. 2011;31:2113–2124.
- Asante CO, Wallace VC, Dickenson AH. Formalin-induced behavioural hypersensitivity and neuronal hyperexcitability are mediated by rapid protein synthesis at the spinal level. Mol Pain. 2009;5:27.
- Jiang Z, Wu S, Wu X, et al. Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via micro-opioid receptor. Int J Cancer. 2016;138:2013–2020.
- Chaplan SR, Bach FW, Pogrel JW, et al. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53:55–63.
- Chen Y, Yang C, Wang ZJ. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience. 2011;193:440–451.
- Al-Batran SE, Ducreux M, Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer. 2012;130:491–496.
- Shor B, Gibbons JJ, Abraham RT, et al. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle. 2009;8:3831–3837.
- Weichhart T, Saemann MD. The multiple facets of mTOR in immunity. Trends Immunol. 2009;30:218–226.
- Xie L, Sun F, Wang J, et al. mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia. J Immunol. 2014;192:6009–6019.
- Li D, Wang C, Yao Y, et al. mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type. Faseb J. 2016;30:3388–3399.
- Soliman GA. The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses. Nutrients. 2013;5:2231–2257.
- Bevan S, Quallo T, Andersson DA. TRPV1. Handb Exp Pharmacol. 2014;222:207–245.
- Lin Q, Li D, Xu X, et al. Roles of TRPV1 and neuropeptidergic receptors in dorsal root reflex-mediated neurogenic inflammation induced by intradermal injection of capsaicin. Mol Pain. 2007;3:30.
- Hua X-Y, Yaksh TL. Dorsal horn substance P and NK1 receptors: study of a model system in spinal nociceptive processing. In: Malcangio M, editor. Synaptic plasticity in pain. New York,NY: Springer Science Business Media; 2009. p. 109–138.
- Chen K, Zhang ZF, Liao MF, et al. Blocking PAR2 attenuates oxaliplatin-induced neuropathic pain via TRPV1 and releases of substance P and CGRP in superficial dorsal horn of spinal cord. J Neurol Sci. 2015;352:62–67.
- Izumi Y, Sasaki M, Hashimoto S, et al. mTOR signaling controls VGLUT2 expression to maintain pain hypersensitivity after tissue injury. Neuroscience. 2015;308:169–179.